Skip Nav Destination
Issues
15 January 2024
-
Cover Image
Cover Image
The cover shows a section of a tumor biopsy from a patient with mismatch repair-deficient colon cancer. Immunohistochemical staining shows tumor-infiltrating CD20+ B cells. For details, see the article by Li and colleagues on page 368 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma
Michael I. Barbato; Jeannette Nashed; Diana Bradford; Yi Ren; Sachia Khasar; Claudia P. Miller; Banu S. Zolnik; Hong Zhao; Yangbing Li; Youwei Bi; Stacy S. Shord; Anup K. Amatya; Pallavi S. Mishra-Kalyani; Barbara Scepura; Raniya A. Al-Matari; Richard Pazdur; Paul G. Kluetz; Martha Donoghue; Harpreet Singh; Nicole Drezner
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
Timil H. Patel; Jamie R. Brewer; Jiaxin Fan; Joyce Cheng; Yuan-Li Shen; Yue Xiang; Hong Zhao; Steven J. Lemery; Richard Pazdur; Paul G. Kluetz; Lola A. Fashoyin-Aje
Clinical Trials: Targeted Therapy
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Johnnie J. Orozco; Phuong T. Vo; Ted A. Gooley; Robyn L. Haaf; Sally J. Lundberg; Donald K. Hamlin; D. Scott Wilbur; Manuela C. Matesan; Darrell R. Fisher; Ajay K. Gopal; Damian J. Green; John M. Pagel; Brenda M. Sandmaier
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Michael S. Petronek; Varun Monga; Kellie L. Bodeker; Michael Kwofie; Chu-Yu Lee; Kranti A. Mapuskar; Jeffrey M. Stolwijk; Amira Zaher; Brett A. Wagner; Mark C. Smith; Sandy Vollstedt; Heather Brown; Meghan L. Chandler; Amanda C. Lorack; Jared S. Wulfekuhle; Jann N. Sarkaria; Ryan T. Flynn; Jeremy D.W. Greenlee; Matthew A. Howard; Brian J. Smith; Karra A. Jones; Garry R. Buettner; Joseph J. Cullen; Joel St-Aubin; John M. Buatti; Vincent A. Magnotta; Douglas R. Spitz; Bryan G. Allen
A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Nuttapong Ngamphaiboon; Poompis Pattaranutaporn; Somthawin Lukerak; Teerada Siripoon; Artit Jinawath; Lalida Arsa; Prapimporn Ch. Shantavasinkul; Naphat Taonam; Narumol Trachu; Natini Jinawath; Arpakorn Kositwattanarerk; Thiparom Sananmuang; Chuleeporn Jiarpinitnun
Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
Vinod Ganju; Gavin Marx; Scott Pattison; Nancy B. Amaro-Mugridge; Jing-Ting Zhao; Bryan R.G. Williams; Jennifer A. MacDiarmid; Himanshu Brahmbhatt
SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Sujana Movva; Sahar Matloob; Elizabeth A. Handorf; Edwin Choy; Priscilla Merriam; Douglas B. Flieder; Kathy Q. Cai; Yan Zhou; Eric D. Tetzlaff; Cheyenne Pagan; Emma Barker; Rosanna Veggeberg; Delia Zumpano; Lori Rink; Margaret von Mehren; Suzanne George
Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Santosh Kesari; Naveed Wagle; Jose A. Carrillo; Akanksha Sharma; Minhdan Nguyen; Judy Truong; Jaya M. Gill; Raffi Nersesian; Natsuko Nomura; Elnaz Rahbarlayegh; Garni Barkhoudarian; Walavan Sivakumar; Daniel F. Kelly; Howard Krauss; Matias A. Bustos; Dave S.B. Hoon; Lars Anker; Arun S. Singh; Kamalesh K. Sankhala; Tiffany M. Juarez
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer
David W. Cescon; John Hilton; Serafin Morales Murilo; Rachel M. Layman; Timothy Pluard; Belinda Yeo; In Hae Park; Louise Provencher; Sung-Bae Kim; Young-Hyuck Im; Anastasia Wyce; Anu Shilpa Krishnatry; Kirsty Hicks; Qu Zhang; Olena Barbash; Ahmed Khaled; Thierry Horner; Arindam Dhar; Mafalda Oliveira; Joseph A. Sparano
Clinical Trials: Immunotherapy
Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Xiaomin Ou; Ruiping Zhai; Wenjun Wei; Jiaying Chen; Dan Ou; Tian Liao; Tingting Xu; Yongxue Zhu; Yulong Wang; Shenglin Huang; Rongliang Shi; Bin Wu; Tongzhen Chen; Yuan Li; Zhongyi Yang; Changming Zhou; Yuan Liu; Ziting Jiang; Min Zeng; Xin Liu; Dongmei Ji; Hongmei Ying; Zhen Zhang; Chaosu Hu; Xueguan Lu; Qinghai Ji; Xiayun He; Yu Wang
Precision Medicine and Imaging
Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Hisham Mehanna; Davy Rapozo; Sandra V. von Zeidler; Kevin J. Harrington; Stuart C. Winter; Andrew Hartley; Paul Nankivell; Andrew G. Schache; Philip Sloan; Edward W. Odell; Selvam Thavaraj; Keith D. Hunter; Ketan A. Shah; Gareth J. Thomas; Anna Long; Rasoul Amel-Kashipaz; Rachel M. Brown; Brendan Conn; Gillian L. Hall; Paul Matthews; Justin Weir; Yen Yeo; Miranda Pring; Catharine M.L. West; James McCaul; Pawel Golusinski; Alice Sitch; Rachel Spruce; Nikolaos Batis; Jennifer L. Bryant; Jill M. Brooks; Terence M. Jones; Francesca Buffa; Syed Haider; Max Robinson
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis
Víctor A. Arrieta; Johnny Duerinck; Kirsten B. Burdett; Karl J. Habashy; Wietse Geens; Andrew Gould; Julia K. Schwarze; Crismita Dmello; Kwang-Soo Kim; Ruth Saganty; Li Chen; Alberto Moscona; Matthew McCord; Catalina Lee-Chang; Craig M. Horbinski; Hui Zhang; Roger Stupp; Bart Neyns; Adam M. Sonabend
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Joseph C. Murray; Lavanya Sivapalan; Karlijn Hummelink; Archana Balan; James R. White; Noushin Niknafs; Lamia Rhymee; Gavin Pereira; Nisha Rao; Benny Weksler; Nathan Bahary; Jillian Phallen; Alessandro Leal; David L. Bartlett; Kristen A. Marrone; Jarushka Naidoo; Akul Goel; Benjamin Levy; Samuel Rosner; Christine L. Hann; Susan C. Scott; Josephine Feliciano; Vincent K. Lam; David S. Ettinger; Qing Kay Li; Peter B. Illei; Kim Monkhorst; Robert B. Scharpf; Julie R. Brahmer; Victor E. Velculescu; Ali H. Zaidi; Patrick M. Forde; Valsamo Anagnostou
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Gazanfer Belge; Cansu Dumlupinar; Tim Nestler; Markus Klemke; Peter Törzsök; Emanuela Trenti; Renate Pichler; Wolfgang Loidl; Yue Che; Andreas Hiester; Cord Matthies; Martin Pichler; Pia Paffenholz; Luis Kluth; Mike Wenzel; Jörg Sommer; Julia Heinzelbecker; Philipp Schriefer; Alexander Winter; Friedemann Zengerling; Mario Wolfgang Kramer; Marie Lengert; Jana Frey; Axel Heidenreich; Christian Wülfing; Arlo Radtke; Klaus-Peter Dieckmann
Translational Cancer Mechanisms and Therapy
CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis
Naema Nayyar; Magali A. de Sauvage; Jane Chuprin; Emily M. Sullivan; Mohini Singh; Consuelo Torrini; Britney S. Zhang; Sushobhana Bandyopadhyay; Keith A. Daniels; Christopher Alvarez-Breckenridge; Ashish Dahal; Michael A. Brehm; Priscilla K. Brastianos
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Giovanni Randon; Yoshiaki Nakamura; Rona Yaeger; Sara Lonardi; Chiara Cremolini; Elena Elez; Federico Nichetti; Filippo Ghelardi; Vincenzo Nasca; Francesca Bergamo; Veronica Conca; Javier Ros; Hideaki Bando; Giulia Maddalena; Simone Oldani; Michele Prisciandaro; Alessandra Raimondi; Alexa B. Schrock; Luca Agnelli; Henry Walch; Takayuki Yoshino; Filippo Pietrantonio
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Seth P. Lerner; David J. McConkey; Catherine M. Tangen; Joshua J. Meeks; Thomas W. Flaig; Xing Hua; Siamak Daneshmand; Ajjai Shivaram Alva; M. Scott Lucia; Dan Theodorescu; Amir Goldkorn; Matthew I. Milowsky; Woonyoung Choi; Rick Bangs; Daniel L. Gustafson; Melissa Plets; Ian M. Thompson, Jr
PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis
Jia Hu; Meera R. Hameed; Narasimhan P. Agaram; Karissa A. Whiting; Li-Xuan Qin; Anthony M. Villano; Rachael B. O'Connor; Julian M. Rozenberg; Sonia Cohen; Katherine Prendergast; Sara Kryeziu; Richard L. White, Jr; Mitchell C. Posner; Nicholas D. Socci; Mrinal M. Gounder; Samuel Singer; Aimee M. Crago
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds